Scholarlink

<p>Biomacromolecules including peptides, proteins, antibodies, and gene medicines, comprise important classes of therapeutics in treating disease. A drawback of biologics is their inconvenient route of administration, as they are mostly injected. Most patients prefer the oral administration route over injections. To accommodate this need, we developed the BIONDD<sup>®</sup> technology, which is an oral administration device for biomacromolecules contained in a standard 00 or 0-sized capsule. Upon ingestion and actuation in the stomach, the macromolecule is delivered from the cavity of the device’s spike into the gastric wall, from where it migrates to the blood vessels. Using 0.4&#xa0;mg liraglutide as a model peptide, a short <i>T</i><sub>max</sub> and a relative oral bioavailability of 119% compared to subcutaneous administration were achieved over time after oral administration of the BIONDD<sup>®</sup> capsule to dogs. The pharmacokinetic data from the large animal studies obtained provides proof-of-concept for a convenient oral delivery device for biologics.</p> Graphical abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Oral capsule administration of biomacromolecules that achieves bioavailability and pharmacokinetics comparable to subcutaneous injection in dogs – the BIONDD® technology

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月28日

查看全文
  • Nikolaj Skak,
  • Nina Mertz,
  • Nils Piwon,
  • Martin R. Olsen,
  • Ester Caffarel-Salvador,
  • David J. Brayden,
  • Jesper Østergaard,
  • Karsten Lindhardt

摘要

Biomacromolecules including peptides, proteins, antibodies, and gene medicines, comprise important classes of therapeutics in treating disease. A drawback of biologics is their inconvenient route of administration, as they are mostly injected. Most patients prefer the oral administration route over injections. To accommodate this need, we developed the BIONDD® technology, which is an oral administration device for biomacromolecules contained in a standard 00 or 0-sized capsule. Upon ingestion and actuation in the stomach, the macromolecule is delivered from the cavity of the device’s spike into the gastric wall, from where it migrates to the blood vessels. Using 0.4 mg liraglutide as a model peptide, a short Tmax and a relative oral bioavailability of 119% compared to subcutaneous administration were achieved over time after oral administration of the BIONDD® capsule to dogs. The pharmacokinetic data from the large animal studies obtained provides proof-of-concept for a convenient oral delivery device for biologics.

Graphical abstract